Tuberculosis diagnostics in 2015: Landscape, priorities, needs, and prospects

Journal of Infectious Diseases

Volumn 211, Issue , 2015, Pages S21-S28

  Pai, Madhukar ^a,b   Schito, Marco ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Diagnostics; Market potential; Pipeline; Tuberculosis; Unmet needs

Indexed keywords

RIFAMPICIN;

ARTICLE; DISEASE COURSE; DISEASE DURATION; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; GENE MUTATION; HEALTH CARE POLICY; HUMAN; MOLECULAR DIAGNOSTICS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS CONTROL; VALIDATION PROCESS; DIAGNOSTIC TEST; ECONOMICS; MEDICAL RESEARCH; MOLECULAR DIAGNOSIS; PROCEDURES; TRENDS;

BIOMEDICAL RESEARCH; DIAGNOSTIC TESTS, ROUTINE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; TUBERCULOSIS;

EID: 84982251454     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu803     Document Type: Article

References (35)

1. World Health Organization. Global tuberculosis report 2014. Geneva: WHO, 2014:1-289.
2. Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Global Health 2014; 2:e453-9.
3. World Health Organization. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization, 2014. http://www.who.int/tb/post2015-TBstrategy.pdf?ua=1. Accessed 29 October 2014.
4. World Health Organization. WHO monitoring of Xpert MTB/RIF rollout. http://www.who.int/tb/laboratory/mtbrifrollout/en/index.html. Accessed 23 October 2014.
5. Steingart K, Schiller I, Horne DJ, Pai M, Boehme C, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; CD009593.
6. UNITAID. Tuberculosis: diagnostics technology and market landscape. 3rd ed. Geneva: WHO, 2014:1-42.
7. Denkinger CM, Kik SV, Pai M. Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countries. Expert Rev Mol Diagn 2013; 13:763-7.
8. Denkinger CM, Nicolau I, Ramsay A, Chedore P, Pai M. Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics? Eur Respir J 2013; 42:544-7.
9. Creswell J, Codlin AJ, Andre E, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis 2014; 14:2.
10. Raizada N, Sachdeva KS, Sreenivas A, et al. Feasibility of decentralised deployment of Xpert MTB/RIF test at lower level of health system in India. PLoS One 2014; 9:e89301.
11. Treatment Action Group & Stop TB Partnership. 2014 Report on tuberculosis research funding: 2005-2013. New York: Treatment Action Group, 2014.
12. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J 2013; 42:708-20.
13. Qin ZZ, Pai M, Van GemertW, Sahu S, Ghiasi M, Creswell J. Eur Respir J 2014:pii:erj01477-2014.
14. Kik SV, Denkinger CM, Casenghi M, Vadnais C, Pai M. Tuberculosis diagnostics: which target product profiles should be prioritised? Eur Respir J 2014; 44:537-40.
15. Pai NP, Vadnais C, Denkinger C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med 2012; 9:e1001306.
16. Pai M. Tuberculosis diagnostics: test developers' FAQs. Int J Tuberc Lung Dis 2013; 17:570-1.
17. Pai M. Diagnostics for tuberculosis: what test developers want to know. Expert Rev Mol Diagn 2013; 13:1-4.
18. Denkinger CM, Kik SV, Cirillo DM, et al. Defining the needs for next generation assays for tuberculosis. J Infect Dis 2015; 211(Suppl 2):S29-38.
19. Denkinger CM, Dolinger D, Schito M, et al. Target Product Profile of a Molecular Drug-Susceptibility Test for Use in Microscopy Centers. J Infect Dis 2015; 211(Suppl 2):S39-49.
20. Kik SV, Denkinger CM, Jefferson C, Ginnard J, Pai M. Potential market for novel tuberculosis diagnostics: worth the investment? J Infect Dis 2015; 211(Suppl 2):S58-66.
21. Pantoja A, Kik SV, Denkinger CM. Costs of novel tuberculosis diagnostics - will countries be able to afford it? J Infect Dis 2015; 211(Suppl 2):S67-77.
22. Wells WA, Boehme CC, Cobelens FG, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013; 13:449-58.
23. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380:986-93.
24. Salamon H, Yamaguchi KD, Cirillo DM, et al. Integration of published information into a resistance-associated mutation database for mycobacterium tuberculosis. J Infect Dis 2015; 211(Suppl 2):S50-7.
25. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013; 12:388-404.
26. Richter E, Rusch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51:1534-6.
27. Denkinger CM, Grenier J, Stratis AK, Akkihal A, Pant-Pai N, Pai M. Mobile health to improve tuberculosis care and control: a call worth making. Int J Tuberc Lung Dis 2013; 17:719-27.
28. Mpofu N, Moyo S, Mulenga H, et al. Time to Symptom Resolution in Young Children Treated for Pulmonary Tuberculosis. Pediatr Infect Dis J 2014; 33:1226-30.
29. Graham SM, Ahmed T, Amanullah F, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 2012; 205(suppl 2):S199-208.
30. Seddon JA, Hesseling AC, Marais BJ, et al. Paediatric use of secondline anti-tuberculosis agents: a review. Tuberculosis (Edinb) 2012; 92:9-17.
31. Xu D, Li Y, Li X, et al. Serum protein S9, SOD3 and MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ-coupled two-dimensional LC-MS/MS. Proteomics 2014; doi:10.1002/pmic. 201400366.
32. Anderson ST, Kaforou M, Brent AJ, et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med 2014; 370:1712-23.
33. Kik SV, Denkinger CM, Chedore P, Pai M. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J 2014; 43:1793-6.
34. TB Diagnostics Market Analysis Consortium. Market assessment of tuberculosis diagnostics in Brazil in 2012. PLoS One 2014; 9:e104105.
35. TB Diagnostics Market Analysis Consortium. Market assessment of tuberculosis diagnostics in South Africa in 2012-2013. Int J Tuberc Lung Dis 2015; 19:216-22.